Barnes Group (B)
(Delayed Data from NYSE)
$42.17 USD
+0.81 (1.96%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $42.11 -0.06 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
B 42.17 +0.81(1.96%)
Will B be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for B based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for B
Strength Seen in Barnes Group (B): Can Its 7.6% Jump Turn into More Strength?
Strength in Aerospace Segment Aids Barnes (B) Amid Cost Woes
B: What are Zacks experts saying now?
Zacks Private Portfolio Services
Barnes (B) Teams Up With RTX's P&WC for Engine Component Repair
Here's Why Hold Strategy is Apt for the Barnes (B) Stock Now
Don't Overlook Barnes Group (B) International Revenue Trends While Assessing the Stock
Other News for B
Leqembi approved for the treatment of Alzheimer's disease in Israel
Leqembi approved for the treatment of Alzheimer's disease in Hong Kong
Leqembi® (lecanemab) launched in China
Truist Financial Issues a Hold Rating on Barnes Group (B)
Joel Murphy Elected to Crawford & Company® Board of Directors